{"created":"2023-06-19T10:30:05.534405+00:00","id":2182,"links":{},"metadata":{"_buckets":{"deposit":"d7d58c33-cdcb-4783-ae85-c08d167b594a"},"_deposit":{"created_by":31,"id":"2182","owners":[31],"pid":{"revision_id":0,"type":"depid","value":"2182"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00002182","sets":["1709617079800:35:686"]},"author_link":["109857","109858","109859","109860","109861","109862","109863","109864","109865","109866","109867","109868","109869","109870","109871","109872","109873","109874","109875","109876"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"145","bibliographicPageStart":"139","bibliographicVolumeNumber":"45","bibliographic_titles":[{"bibliographic_title":"川崎医学会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_description_33":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"原著論文","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10001_description_34":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Regular Article","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"川崎医学会","subitem_publisher_language":"ja"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-J201945139","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://igakkai.kms-igakkai.com/wp/wp-content/uploads/2019/KMJ-J201945139.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_relation_35":{"attribute_name":"医中誌ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"2020200387","subitem_relation_type_select":"ICHUSHI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00045593","subitem_source_identifier_type":"NCID"},{"subitem_source_identifier":"AN12940574","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0386-5924","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2758-089X","subitem_source_identifier_type":"EISSN"}]},"item_10001_text_31":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"}]},"item_10001_text_32":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"}]},"item_10001_textarea_5":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"　The humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab has been used to treat advanced or metastatic breast cancer since 2011 in Japan. According to the Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer 2018, the addition of bevacizumab to first- or second-line chemotherapy is recommended for patients with human epidermal growth factor receptor (HER) 2-negative advanced or metastatic breast cancer. We investigated the clinical utility of combined bevacizumab and paclitaxel therapy (BP therapy) for patients with advanced or metastatic breast cancer at our hospital. The study subjects were 79 breast cancer patients who received BP therapy at our hospital between September 2011 and October 2018, and their medical records were retrospectively reviewed. The median age of the subjects was 58 years old. Their primary tumors were categorized as follows: the hormone receptor (HR)-positive, HER2- negative subtype in 45 patients, the HR-positive, HER2-positive subtype in 2 patients, the HR-negative, HER2-positive subtype in 5 patients, and the HR-negative, HER2-negative (socalled triple-negative) subtype in 27 patients. Twenty-four patients had stage IV disease and 55 had recurrent disease. The main metastatic lesions were in bone in 45 patients, in the liver in 34 patients, in the lungs in 29 patients, and in pleura in 21 patients. The median number of previous chemotherapeutic regimens was 2 (range: 0-8). The objective response rate was 63.3%, the median progression-free survival (PFS) time was 5.4 months, and the median overall survival (OS) time was 9.4 months. Multivariate analyses of predictive factors for PFS or OS in HER2-negative subjects revealed a performance status of 2 or higher to be a significant predictor of poor OS (hazard ratio [HR]=2.85, p=0.002), and the triple-negative subtype and metastasis to the central nervous system to be predictors of poor PFS (HR=2.44，p=0.025 for the former and HR=3.24，p=0.045 for the latter). Serious adverse events, such as perforation of the gastrointestinal tract, ulcer formation in the skin and soft tissue, fistula formation between the trachea and mediastinum, pulmonary abscess, intracranial hemorrhage, gastrointestinal bleeding, macro-hematuria, and nasal bleeding, were observed during BP therapy. Most patients in this study received BP therapy as greater than second-line therapy; therefore, the PFS was slightly shorter, but the ORR was similar to that previously reported. As serious adverse events were observed in more than 10% of the study subjects, physicians should pay close attention during BP therapy."}]},"item_10001_textarea_6":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_textarea_language":"ja","subitem_textarea_value":"　抗血管内皮増殖因子（vascular endothelial growth factor, VEGF）モノクローナル抗体ベバシズマブが進行・再発乳癌の治療薬として日本においても2011年から使用されている．日本乳癌学会乳癌診療ガイドライン2018年においてHER2陰性転移・再発乳癌に対する１次・２次の化学療法にベバシズマブを併用することが推奨されている．今回，当院における進行・転移再発乳癌に対するベバシズマブとパクリタキセル同時併用療法（BP 療法）の有用性の検討を行った．対象患者は2011年９月～2018年10月に当科でBP 療法を導入した79症例で，電子カルテを参照して後方視的検討を行った．年齢の中央値は58歳．ホルモン受容体（hormone receptor, HR）陽性humanepidermal growth factor receptor（HER）２陰性サブタイプが45例，HR 陽性HER2陽性サブタイプが２例，HR 陰性HER2陽性サブタイプが５例，HR 陰性HER2陰性（triple negative）サブタイプが27例であった．Stage Ⅳが24例，再発が55例であり，主な転移部位（重複あり）は骨が45例，肝が34例，肺が29例，胸膜が21例であった．前化学療法レジメン数の中央値は２レジメン（範囲：0-8）であった．奏効率は63.3%，無増悪生存期間（PFS）の中央値は5.4か月であり，全生存期間（OS）の中央値は9.4か月であった．HER2陰性症例における多変量解析の結果，performance status 2以上がOS を悪化させる因子であり（ハザード比 [HR] が2.85， p=0.002），triple negative サブタイプ（HR が2.44，p=0.025）と中枢神経転移あり（HR が3.24，p=0.045）がPFS を悪化させる因子であった．重篤な有害事象としては，消化管穿孔と皮膚・軟部組織潰瘍形成，縦隔気管瘻，肺膿瘍，脳出血，上部消化管出血，血尿，鼻出血が認められた．本研究対象は２次治療以降で使用された症例が多いため，既報の臨床試験の結果と比較するとPFS は短かったが，奏効率は同等であった．一方，重篤な有害事象も10% 以上の頻度で認められ，BP 療法施行時には慎重な観察が必要である．"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"齋藤, 亙","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"福間, 佑菜","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"三上, 剛司","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"岸野, 瑛美","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"緒方, 良平","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小池, 良和","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"野村, 長久","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山本, 裕","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"田中, 克浩","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"紅林, 淳一","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SAITO, Wataru","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"FUKUMA, Yuna","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MIKAMI, Tsuyoshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KISHINO, Emi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OGATA, Ryohei","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KOIKE, Yoshikazu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NOMURA, Tsunehisa","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAMOTO, Yutaka","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TANAKA, Katsuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KUREBAYASHI, Junichi","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-04-01"}],"displaytype":"detail","filename":"KMJ-J201945139.pdf","filesize":[{"value":"1.3 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","objectType":"fulltext","url":"https://kwmed.repo.nii.ac.jp/record/2182/files/KMJ-J201945139.pdf"},"version_id":"920d219e-5c8b-4d3b-b3c3-76fa35120787"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"転移乳癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"再発乳癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"ベバシズマブ","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"パクリタキセル","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"治療効果","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"Metastatic breast cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Recurrent breast cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Bevacizumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Paclitaxel","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Efficacy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"当院における進行・再発乳癌に対するベバシズマブ・パクリタキセル併用療法の有用性の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"当院における進行・再発乳癌に対するベバシズマブ・パクリタキセル併用療法の有用性の検討","subitem_title_language":"ja"},{"subitem_title":"Utility of bevacizumab plus paclitaxel therapy for patients with advanced or recurrent breast cancer treated at our hospital","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"31","path":["686"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-04-01"},"publish_date":"2020-04-01","publish_status":"0","recid":"2182","relation_version_is_last":true,"title":["当院における進行・再発乳癌に対するベバシズマブ・パクリタキセル併用療法の有用性の検討"],"weko_creator_id":"31","weko_shared_id":-1},"updated":"2024-04-19T04:11:27.074349+00:00"}